期刊文献+

Apolipoprotein J: A New Predictor and Therapeutic Target in Cardiovascular Disease? 被引量:9

Apolipoprotein J: A New Predictor and Therapeutic Target in Cardiovascular Disease?
原文传递
导出
摘要 Objective: To review the functional mechanism of apolipoprotein J (apoJ) in the process of atherosclerosis and the feasibility of apoJ as a therapeutic endpoint. Data Sources: Relevant articles published in English from 1983 to present were selected from PubMed. The terms of"atherosclerosis. apolipoprotein J, clusterin (CLU), oxidative stress, and inflammation" were used for searching. Study Selection: Articles studying the role ofapoJ with atherosclerosis and restenosis after injury were reviewed. Articles focusing on the intrinsic determinants of atherosclerosis were selected. The exclusion criteria of articles were that the studies on immunologic vasculitis. Results: ApoJ, involved in numerous physiological process important for lipid transportation and vascular smooth muscle cell differentiation, including apoptotic cell death, cell-cycle regulation, cell adhesion, tissue remodeling, immune system regulation, and oxidative stress, plays a role in the development of clinical atherosclerosis. In the process of relieving atherosclerosis, apoJ can promote cholesterol and phospholipid export from macrophage-foam cells, and exhibit cytoprotective and anti-inflammatory actions by interacting with lots of known inflammatory proteins which may predict the onset of clinical cardiovascular events and may actually play a causal role in mediating atherosclerotic disease such as C-reactive protein, paraoxonase, and leptin. As known as CLU, apoJ has been identified to play central roles in the process of vascular smooth cells migration, adhesion, and proliferation, which can contribute significantly to restenosis atter vascular injury. Conclusions: Intense effort and substantial progress have been made to identify the apoJ that relieves atherosclerosis and vascular restenosis after percutaneous coronary intervention. More work is needed to elucidate the exact mechanisms of and the interrelationship between the actions ofapoJ and to successfully achieve regression ofatherosclerosis by regarding it as a therapeutic endpoint. Objective: To review the functional mechanism of apolipoprotein J (apoJ) in the process of atherosclerosis and the feasibility of apoJ as a therapeutic endpoint. Data Sources: Relevant articles published in English from 1983 to present were selected from PubMed. The terms of"atherosclerosis. apolipoprotein J, clusterin (CLU), oxidative stress, and inflammation" were used for searching. Study Selection: Articles studying the role ofapoJ with atherosclerosis and restenosis after injury were reviewed. Articles focusing on the intrinsic determinants of atherosclerosis were selected. The exclusion criteria of articles were that the studies on immunologic vasculitis. Results: ApoJ, involved in numerous physiological process important for lipid transportation and vascular smooth muscle cell differentiation, including apoptotic cell death, cell-cycle regulation, cell adhesion, tissue remodeling, immune system regulation, and oxidative stress, plays a role in the development of clinical atherosclerosis. In the process of relieving atherosclerosis, apoJ can promote cholesterol and phospholipid export from macrophage-foam cells, and exhibit cytoprotective and anti-inflammatory actions by interacting with lots of known inflammatory proteins which may predict the onset of clinical cardiovascular events and may actually play a causal role in mediating atherosclerotic disease such as C-reactive protein, paraoxonase, and leptin. As known as CLU, apoJ has been identified to play central roles in the process of vascular smooth cells migration, adhesion, and proliferation, which can contribute significantly to restenosis atter vascular injury. Conclusions: Intense effort and substantial progress have been made to identify the apoJ that relieves atherosclerosis and vascular restenosis after percutaneous coronary intervention. More work is needed to elucidate the exact mechanisms of and the interrelationship between the actions ofapoJ and to successfully achieve regression ofatherosclerosis by regarding it as a therapeutic endpoint.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2015年第18期2530-2534,共5页 中华医学杂志(英文版)
基金 a grant of the Key Technology and Science Foundation of Tianjin,China
关键词 Apolipoprotein J ATHEROSCLEROSIS Coronary Artery Disease: Inflammation RESTENOSIS Apolipoprotein J Atherosclerosis Coronary Artery Disease: Inflammation Restenosis
  • 相关文献

参考文献38

  • 1Coronary Heart Disease-Auses, Symptoms, Prevention. Southern Cross Healthcare Group, 2013. Available from: https://www.southerncross.co.nz/AboutTheGroup/HealthResources/MedicalLibrary/tabid/178/vw/1/ItemID/191/Coronary-heart-disease-causes-symptoms-prevention.aspx. [Last accessed on 2014 Nov 11].
  • 2Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age : Statistics from World Health Organisation and United Nations. Int J Cardiol 2013;168:934-45.
  • 3World Health Organization, Department of Health Statistics and Informatics in the Information, Evidence and Research Cluster. The Global Burden of Disease 2004 Update. Geneva: World Health Organization; 2004.
  • 4Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006;113:1140-50.
  • 5Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98:1352-64.
  • 6Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease : Role of high-density lipoprotein-proteome remodeling. Circulation 2013;127:891-904.
  • 7Koltai T. Clusterin : A key player in cancer chemoresistance and its inhibition. Onco Targets Ther 2014;7:447-56.
  • 8Bettuzzi S. Conclusions and perspectives. Adv Cancer Res 2009;105:133-50.
  • 9Baralla A, Sotgiu E, Deiana M, Pasella S, Pinna S, Mannu A, et al. Plasma clusterin and lipid profile: A link with aging and cardiovascular diseases in a population with a consistent number of centenarians. PLoS One 2015;10:e0128029.
  • 10Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002;34:1430-48.

同被引文献31

引证文献9

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部